In the Know.

Slides:

Advertisements

Similar presentations

What's New in Basal Insulin for Diabetes

Advertisements

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Applying Data to Practice

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

Updates on Emerging GLP-1 Receptor Agonists

Updates on CVOT Data and Clinical Comparisons That Matter

SGLT2 Inhibitors and Their Clinical Impact:

Global Projections for Diabetes:

What Comes Second?.

Insulin Innovation.

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Updates on Outcomes for Novel T2D Therapies

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Examining CV Effects of Basal Insulin Therapy

What Do We Know About LDL-C?

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Emerging CVOT Data and Clinical Application

How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Impacting CV Risk With Diabetes Medications

Impacting CV Risk With Diabetes Medications

GLP-1 Receptor Agonists: How Early Is Appropriate?

A Deep Dive Into CVOTs.

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Growing Diabetes Pandemic Worldwide

Tackling CV Risk in T2DM.

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Breaking Down the CVOTs

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Insulin Innovation.

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

LEADER One Year On.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Learning Objectives Metabolic Abnormalities Associated With T2D.

Antihyperglycemic Therapy

CV Outcomes and Adherence With GLP-1 RAs

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Oral Combination Therapy for T2D

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Updates From ACC.

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Improving Overall Health

Completed and ongoing CVOTs (6–14,39,44–58)

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

What's New in Oral Combination Therapy for Type 2 Diabetes?

Challenges and Emerging Solutions in Anemia Management Explored

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Presentation transcript:

In the Know

The GLP-1 RA Class for Type 2 Diabetes

Beyond Glycemic Control: Impact of CVOT Data on Clinical Recommendations for T2D

Although Both are Incretin-Based Therapies, GLP-1 RAs and DPP-4 Inhibitors Have Different Effects

Despite Their Proven Efficacy, Currently Available GLP-1 RAs Are Still Underutilized

Novel Mechanism of Action of Oral Semaglutide: Tablet Coformulation with SNAC

Administration of Oral Semaglutide

Other Novel GLP-1 RAs

PIONEER 1-10 Clinical Program

PIONEER 2, 3, 4, and 7: Oral Semaglutide vs Active Comparators

Summary of Oral Semaglutide Comparative Studies

PIONEER 6: CVOT of Oral Semaglutide

PIONEER 6: Non-Significant Reduction in MACE and Significant Reduction in Death From CV Causes

What to Look Forward To

Abbreviations

Abbreviations (cont)